Kindred Unsuccessful With First Canine Drug
August 21, 2014
Kindred Biosciences Inc. has been dealt a setback with the discovery that the startup drug company’s vanguard product, CereKin, failed a pivotal field study. The Burlingame, Calif., company had hoped to achieve U.S. Food and Drug Administration approval of CereKin (diacerein) for the control of osteoarthritic pain and inflammation in dogs sometime in 2015. Kindred… Continue reading...